mbi-226 profile

omiganan pentahydrochloride: a cationic peptide with antibacterial activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	16131446
CHEMBL ID	1793889
MeSH ID	M0456377

Synonym
269062-93-3
CHEMBL1793889
omiganan pentahydrochloride
626233-83-8
mbi-226
l-isoleucyl-l-leucyl-l-arginyl-l-tryptophyl-l-prolyl-l-tryptophyl-l-tryptophyl-l-prolyl-l-tryptophyl-l-arginyl-l-arginyl-l-lysinamide pentahydrochloride
omiganan hcl
mbi 226
l-lysinamide, l-isoleucyl-l-leucyl-l-arginyl-l-tryptophyl-l-prolyl-l-tryptophyl-l-tryptophyl-l-prolyl-l-tryptophyl-l-arginyl-l-arginyl-, pentahydrochloride
omiganan pentahydrochloride [usan]
lx2p9rd54v ,
unii-lx2p9rd54v
l-lysinamide, l-isoleucyl-l-leucyl-l-arginyl-l-tryptophyl-l-prolyl-l-tryptophyl-l-tryptophyl-l-prolyl-l-tryptophyl-l-arginyl-l-arginyl-, hydrochloride (1:5)
EX-A7464

Bioassays (94)

Assay ID	Title	Year	Journal	Article
AID1060569	Antibacterial activity against Pseudomonas aeruginosa M7728 clinical isolate expressing blaIMP gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519053	Antifungal activity against Paecilomyces variotii after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060517	Antibacterial activity against Staphylococcus saprophyticus M2981 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060533	Antibacterial activity against Staphylococcus aureus ATCC 29213 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519052	Antifungal activity against Fusarium sp. after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060502	Antibacterial activity against Enterococcus faecium PZAP95 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060547	Antibacterial activity against Klebsiella pneumoniae M1803 clinical isolate expressing blaPER-2, blaCTX-M-2, blaTEM-1, blaSHV and blaOXA-9 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519047	Antifungal activity against Candida krusei after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060556	Antibacterial activity against Acinetobacter sp. M7978 clinical isolate expressing blaIMP-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060529	Antibacterial activity against Staphylococcus aureus M6276 clinical isolate expressing ermA and lnuA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060555	Antibacterial activity against Acinetobacter sp. M9013 clinical isolate expressing blaOXA-51 and blaIMP gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060578	Antibacterial activity against Enterococcus gallinarum M2723 clinical isolate expressing vanC1 and vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060543	Antibacterial activity against Klebsiella pneumoniae M11245 clinical isolate expressing blaKPC-2 and blaPER-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060525	Antibacterial activity against Staphylococcus aureus M4046 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060560	Antibacterial activity against Acinetobacter sp. M7489 clinical isolate expressing blaOXA-51 and blaTEM gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519054	Antifungal activity against Penicillium marneffei after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060527	Antibacterial activity against Staphylococcus aureus M6794 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060557	Antibacterial activity against Acinetobacter sp. M5949 clinical isolate expressing blaOXA-23 and blaOXA-GVI gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060507	Antibacterial activity against Enterococcus faecalis M6534 clinical isolate expressing vanB gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060539	Antibacterial activity against Escherichia coli PNEU23 clinical isolate expressing blaOXA-GIII and blaTEM-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060573	Antibacterial activity against Pseudomonas aeruginosa M7907 clinical isolate expressing blaPER gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID521787	Antifungal activity against Candida albicans after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID519046	Antifungal activity against Candida glabrata after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060558	Antibacterial activity against Acinetobacter sp. M5277 clinical isolate expressing blaPER gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060566	Antibacterial activity against Pseudomonas aeruginosa M7525 clinical isolate expressing blaSPM gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519050	Antifungal activity against Aspergillus sp. after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID519049	Antifungal activity against Candida tropicalis after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060515	Antibacterial activity against Staphylococcus haemolyticus M3014 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060501	Antibacterial activity against Enterococcus faecium M2619 clinical isolate expressing vanB gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060508	Antibacterial activity against Enterococcus faecalis M4899 clinical isolate expressing vanB gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060538	Antibacterial activity against Escherichia coli PCOS15 clinical isolate expressing blaPER-2 and blaTEM-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060550	Antibacterial activity against Klebsiella pneumoniae M5825 clinical isolate expressing blaGES-3 and blaCTX-M-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060554	Antibacterial activity against Klebsiella pneumoniae PFAV3 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060506	Antibacterial activity against Enterococcus faecalis M4992 clinical isolate expressing vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060542	Antibacterial activity against Escherichia coli ATCC 25922 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060561	Antibacterial activity against Acinetobacter sp. M5179 clinical isolate expressing blaOXA-51 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060574	Antibacterial activity against Pseudomonas aeruginosa M5470 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060549	Antibacterial activity against Klebsiella pneumoniae M9310 clinical isolate expressing blaCTX-M-2, blaTEM-1 and blaSHV-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060532	Antibacterial activity against Staphylococcus aureus P33 clinical isolate expressing msrA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060575	Antibacterial activity against Pseudomonas aeruginosa PCOS12 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060513	Antibacterial activity against Staphylococcus hominis M2967 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060576	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060534	Antibacterial activity against Escherichia coli M9209 clinical isolate expressing blaKPC-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060552	Antibacterial activity against Klebsiella pneumoniae M9491 clinical isolate expressing blaMOX gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519051	Antifungal activity against Curvularia species after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060537	Antibacterial activity against Escherichia coli PABC11 clinical isolate expressing blaCTX-M-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519055	Antifungal activity against Penicillium sp. after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060510	Antibacterial activity against Enterococcus faecalis ATCC 29212 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060528	Antibacterial activity against Staphylococcus aureus P239 clinical isolate expressing ermC gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060581	Antibacterial activity against Enterococcus faecium M2304 clinical isolate expressing vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID519048	Antifungal activity against Candida parapsilosis after 48 hrs by broth microdilution	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
AID1060505	Antibacterial activity against Enterococcus faecalis M6383 clinical isolate expressing vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060526	Antibacterial activity against Staphylococcus aureus M2832 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060519	Antibacterial activity against Staphylococcus epidermidis M2921 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060559	Antibacterial activity against Acinetobacter sp. PFAV1 clinical isolate expressing blaOXA-51, blaOXA-58 and blaPER gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060548	Antibacterial activity against Klebsiella pneumoniae M9375 clinical isolate expressing blaCTX-M-2, blaTEM-1 and blaSHV-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060518	Antibacterial activity against Staphylococcus saprophyticus M4070 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060565	Antibacterial activity against Pseudomonas aeruginosa M7712 clinical isolate expressing blaSPM gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060512	Antibacterial activity against Staphylococcus warneri M6823 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060540	Antibacterial activity against Escherichia coli M7859 clinical isolate expressing blaCIT gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060564	Antibacterial activity against Acinetobacter sp. M13523 clinical isolate expressing blaOXA-51 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060520	Antibacterial activity against Staphylococcus epidermidis M2919 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060531	Antibacterial activity against Staphylococcus aureus P28 clinical isolate expressing ermA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060541	Antibacterial activity against Escherichia coli M9884 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060514	Antibacterial activity against Staphylococcus hominis M2973 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060570	Antibacterial activity against Pseudomonas aeruginosa M7723 clinical isolate expressing blaKPC-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060563	Antibacterial activity against Acinetobacter sp. M9665 clinical isolate expressing blaOXA-51 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060544	Antibacterial activity against Klebsiella pneumoniae M9885 clinical isolate expressing blaKPC-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060568	Antibacterial activity against Pseudomonas aeruginosa M5109 clinical isolate expressing blaVIM and blaGES-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060523	Antibacterial activity against Staphylococcus aureus M6784 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060504	Antibacterial activity against Enterococcus faecalis M4449 clinical isolate expressing vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060545	Antibacterial activity against Klebsiella pneumoniae M13540 clinical isolate expressing blaKPC-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060509	Antibacterial activity against Enterococcus faecalis ATCC 51299 clinical isolate expressing vanB gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060500	Antibacterial activity against Enterococcus faecium M6261 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060522	Antibacterial activity against Staphylococcus epidermidis M2923 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060499	Antibacterial activity against Enterococcus faecium M2481 clinical isolate expressing vanB gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060577	Toxicity in human RBC assessed as hemolytic activity relative to control	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060567	Antibacterial activity against Pseudomonas aeruginosa M5200 clinical isolate expressing blaVIM and blaGES-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060562	Antibacterial activity against Acinetobacter sp. M5282 clinical isolate expressing blaOXA-51 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060579	Antibacterial activity against Enterococcus gallinarum M2685 clinical isolate expressing vanC1 and vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060530	Antibacterial activity against Staphylococcus aureus P204 clinical isolate expressing ermA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060553	Antibacterial activity against Klebsiella pneumoniae M9140 clinical isolate expressing blaCIT gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060580	Antibacterial activity against Enterococcus faecium M2664 clinical isolate expressing vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060571	Antibacterial activity against Pseudomonas aeruginosa M11005 clinical isolate expressing blaKPC-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060521	Antibacterial activity against Staphylococcus epidermidis M2931 by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060524	Antibacterial activity against Staphylococcus aureus M6820 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060536	Antibacterial activity against Escherichia coli PLCA1 clinical isolate expressing blaCTX-M-2 and blaTEM-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060503	Antibacterial activity against Enterococcus faecalis M6983 clinical isolate expressing vanA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060535	Antibacterial activity against Escherichia coli M5306 clinical isolate expressing blaPER-2, blaCTX-M-2 and blaTEM-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060572	Antibacterial activity against Pseudomonas aeruginosa M13513 clinical isolate expressing blaKPC-2 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060516	Antibacterial activity against Staphylococcus haemolyticus M2976 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060551	Antibacterial activity against Klebsiella pneumoniae M9170 clinical isolate expressing blaOXA-GIII gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060546	Antibacterial activity against Klebsiella pneumoniae M7647 clinical isolate expressing blaVIM, blaCTX-M-2, blaTEM-1 and blaSHV-1 gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
AID1060511	Antibacterial activity against Staphylococcus cohnii M6767 clinical isolate expressing mecA gene by microdilution test	2014	European journal of medicinal chemistry, Jan, Volume: 71	Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (69.23)	29.6817
2010's	3 (23.08)	24.3611
2020's	1 (7.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (7.14%)	5.53%
Reviews	3 (21.43%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (71.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.04	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	2.04	1	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
itraconazole [no description available]	2.04	1	piperazines
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	2.02	1	penicillin	antibacterial agent; antibacterial drug
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	2.04	1	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
glycidyl nitrate glycidyl nitrate: a nitric oxide donor; structure in first source. peptidoglycan : A peptidoglycosaminoglycan formed by alternating residues of beta-(1->4)-linked N-acetylglucosamine and N-acetylmuramic acid {2-amino-3-O-[(S)-1-carboxyethyl]-2-deoxy-D-glucose} residues. Attached to the carboxy group of the muramic acid is a peptide chain of three to five amino acids.	2.03	1
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.04	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
1-palmitoyl-2-oleoylphosphatidylcholine 1-palmitoyl-2-oleoylphosphatidylcholine: RN given refers to (Z)-isomer	2.03	1
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	2.04	1	nystatins
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2.03	1	1,2-diacyl-sn-glycero-3-phosphocholine
indolicidin [no description available]	3.13	1

Condition	Relationship Strength	Studies	Trials
Aspergillus Infection [description not available]	2.04	1	0
Candida Infection [description not available]	2.43	2	0
Fungemia The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy.	2.04	1	0
Aspergillosis Infections with fungi of the genus ASPERGILLUS.	2.04	1	0
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	2.43	2	0
Bacterial Disease [description not available]	3.65	3	0
Bacterial Infections Infections by bacteria, general or unspecified.	3.65	3	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.05	1	0
Extravascular Hemolysis [description not available]	2.06	1	0
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	2.06	1	0
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	4.31	1	1
Infections, Staphylococcal [description not available]	2.04	1	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.04	1	0
Acne [description not available]	2.94	1	0
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	2.94	1	0

mbi-226

Description

Cross-References

Synonyms (14)

Bioassays (94)

Research

Studies (13)

Study Types

mbi-226

Description

Cross-References

Synonyms (14)

Bioassays (94)

Research

Studies (13)

Study Types

Related Drugs (11)

Related Conditions (15)